검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | all trans Retinoic Acid (all trans Retinoic Acid) Hackensack Meridian Health·Colorectal Cancer ORR 50% |
|---|---|
Overview Program | all trans Retinoic Acid |
Overview Company | Hackensack Meridian Health |
Overview Modality | ANTIBODY |
Overview Target | Colorectal Cancer |
Overview Indication | Multiple Myeloma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | target effects, toxicity, and high costs, particularly with antigen |
MoA Biomarker | biomarkers of RA exposure, improved isoform, and tissue selectivity, and trial designs that incorporate RA au |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | ATPR promotes differentiation in gastric cancer cells by endocan.. ATPR (4-amino-2-trifluoromethyl-phenyl retinate), a derivative of ATRA (all-trans retinoic acid), exhibits potent anti-cancer activity by restoring the differentiation capacity of tumor cells. It has lower cytotoxicity compared to ATRA, making it a clinically valuable therapeutic agent. Endocan, encoded by ESM-1, a glycoprotein sec… |
Clinical Primary efficacy | ORR 50% |
Clinical ORR | 100.0% |
Clinical OS | NA |
Clinical Result source | ClinicalTrials.gov NCT02842827 |
Clinical Data Tier / Score | A · 56 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (2일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | all trans Retinoic Acid (all trans Retinoic Acid) Hackensack Meridian Health·Colorectal Cancer ORR 50% |
|---|---|
Overview Program | all trans Retinoic Acid |
Overview Company | Hackensack Meridian Health |
Overview Modality | ANTIBODY |
Overview Target | Colorectal Cancer |
Overview Indication | Multiple Myeloma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | target effects, toxicity, and high costs, particularly with antigen |
MoA Biomarker | biomarkers of RA exposure, improved isoform, and tissue selectivity, and trial designs that incorporate RA au |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | ATPR promotes differentiation in gastric cancer cells by endocan.. ATPR (4-amino-2-trifluoromethyl-phenyl retinate), a derivative of ATRA (all-trans retinoic acid), exhibits potent anti-cancer activity by restoring the differentiation capacity of tumor cells. It has lower cytotoxicity compared to ATRA, making it a clinically valuable therapeutic agent. Endocan, encoded by ESM-1, a glycoprotein sec… |
Clinical Primary efficacy | ORR 50% |
Clinical ORR | 100.0% |
Clinical OS | NA |
Clinical Result source | ClinicalTrials.gov NCT02842827 |
Clinical Data Tier / Score | A · 56 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (2일 전) |
추천 비교
추천 비교